SciELO - Scientific Electronic Library Online

 
vol.63 número4Jaques-Louis Reverdin (1842-1929): el cirujano y la agujaHallazgos bioquímico-histo-morfométricos de la próstata residual (III): PSA "indetectable" mantenido tras adenomectomía retropúbica por HBP índice de autoresíndice de materiabúsqueda de artículos
Home Pagelista alfabética de revistas  

Servicios Personalizados

Articulo

Indicadores

Links relacionados

  • En proceso de indezaciónCitado por Google
  • No hay articulos similaresSimilares en SciELO
  • En proceso de indezaciónSimilares en Google

Compartir


Archivos Españoles de Urología (Ed. impresa)

versión impresa ISSN 0004-0614

Resumen

HERRANZ AMO, Felipe. Comparative analysis of six months formulation of LHRH analogues for prostate cancer treatment. Arch. Esp. Urol. [online]. 2010, vol.63, n.4, pp.275-284. ISSN 0004-0614.

Objectives: To perform comparative analysis of the efficacy and the safety of six months formulation of LHRH analogues indicated for prostate cancer treatment. Method: Search in the PubMed database for clinical trials published between 2006 and 2009 using the following key words: "prostate cancer", "triptorelin or leuprorelin" and "6-month depot". Results: The efficacy of all 3 six months formulation of LHRH analogues currently approved is high (96-98%) for reducing testosterone levels down to below 50 ng/dl. As the patients included in the three trials are quite heterogeneous, and due to the variability in the way of presenting results, it is not possible to compare testosterone escapes and their effect on PSA levels. The incidence of adverse events (AE) reported across the three trials was high, but only 0.9% to 15.8% were severe. Only one trial reported patient withdrawal (2.5%) because of drug-related AEs. Conclusion: Even though all the studies show and important variability in the analysis and data management, no significant efficacy and safety differences seem to exist.

Palabras clave : Prostate cancer; LHRH analogue; Semiannual administration; Efficacy; Safety.

        · resumen en Español     · texto en Español     · Español ( pdf )

 

Creative Commons License Todo el contenido de esta revista, excepto dónde está identificado, está bajo una Licencia Creative Commons